Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Other

Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression

PDT treatment caused tumour growth arrest in all the tumours despite the tumours having a clinically defined low/negative HER2 expression level.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors developed an antibody-photosensitizer conjugate targeting HER2 and tested it in cells and in a mouse model of human oesophageal adenocarcinoma with low HER2 expression. They report selective binding to tumour over normal tissue, light-dependent cell killing in vitro, and tumour growth arrest after treatment in vivo. The study was conducted in cells and mice, so its relevance to human patients is not established.

Who or what was studied
Human oesophageal adenocarcinoma cells and a mouse xenograft model with low or negative HER2 expression
Limits stated in the abstract
The findings come from in vitro and mouse xenograft work rather than human participants, and the abstract gives no sample size.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Early oesophageal adenocarcinoma (OA) and pre-neoplastic dysplasia may be treated with endoscopic resection and ablative techniques such as photodynamic therapy (PDT). Though effective, discrete areas of disease may be missed leading to recurrence. PDT further suffers from the side effects of off-target photosensitivity. A tumour specific and light targeted therapeutic agent with optimised pharmacokinetics could be used to destroy residual cancerous cells left behind after resection. A small molecule antibody-photosensitizer conjugate was developed targeting human epidermal growth factor receptor 2 (HER2). This was tested in an in vivo mouse model of human OA using a xenograft flank model with clinically relevant low level HER2 expression and heterogeneity. In vitro we demonstrate selective binding of the conjugate to tumour versus normal tissue. Light dependent cytotoxicity of the phototherapy agent in vitro was observed. In an in vivo OA mouse xenograft model the phototherapy agent had desirable pharmacokinetic properties for tumour uptake and blood clearance time. PDT treatment caused tumour growth arrest in all the tumours despite the tumours having a clinically defined low/negative HER2 expression level. This new phototherapy agent shows therapeutic potential for treatment of both HER2 positive and borderline/negative OA.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Phototherapy, Photodynamic therapy, Heterogeneity. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies